Decoding innate immune signaling in normal and myelodysplastic hematopoiesis

解码正常和骨髓增生异常造血中的先天免疫信号

基本信息

  • 批准号:
    10571337
  • 负责人:
  • 金额:
    $ 111.3万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2023
  • 资助国家:
    美国
  • 起止时间:
    2023-01-01 至 2029-12-31
  • 项目状态:
    未结题

项目摘要

Abstract Myelodysplastic Syndromes (MDS) are heterogenous and poorly understood hematopoietic stem cell (HSC) failure syndromes common in individuals >60 years of age. With increased life expectancies, the incidence of MDS continues to rise, and will soon be the most prevalent hematologic disorder in elderly. There are no effective treatments for MDS patients, due to an insufficient understanding of the underlying pathobiology and a lack of faithful mouse models. Our research program is focused on filling these gaps, and then leveraging the resulting knowledge and tools to develop effective drug therapies. Already, we have discovered genetically-driven aberrant activation of innate immune pathways in MDS HSCs. We have also identified a critical function of innate immune pathways in normal HSCs, which has implications for chronic immune-related disorders, cardiovascular diseases, and hematopoiesis. We hypothesize that dysregulated innate immune signaling is a major contributor to the initiation and development of MDS, and is a feasible therapeutic target. Herein, we propose to test this hypothesis by carrying out the following complimentary 3-part research program: (1) Dissect the genetic and cellular underpinnings of MDS HSCs, with an emphasis on cell-intrinsic and cell-extrinsic immune-inflammatory factors. (2) Identify and characterize novel signaling pathways driving MDS phenotype in HSCs. (3) Develop novel therapeutic strategies for the treatment of MDS. The results of our research program will advance our paradigm-shifting model of the initiation, progression, and treatment of MDS.
摘要

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Daniel Starczynowski其他文献

Daniel Starczynowski的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Daniel Starczynowski', 18)}}的其他基金

Therapeutic targeting of IRAK4 in MDS
MDS 中 IRAK4 的治疗靶向
  • 批准号:
    10696208
  • 财政年份:
    2022
  • 资助金额:
    $ 111.3万
  • 项目类别:
Therapeutic targeting of IRAK4 in MDS
MDS 中 IRAK4 的治疗靶向
  • 批准号:
    10537837
  • 财政年份:
    2022
  • 资助金额:
    $ 111.3万
  • 项目类别:
Xenotransplant and Genome Editing Core
异种移植和基因组编辑核心
  • 批准号:
    10201887
  • 财政年份:
    2021
  • 资助金额:
    $ 111.3万
  • 项目类别:
Cincinnati Cooperative Center of Excellence in Hematology
辛辛那提血液学卓越合作中心
  • 批准号:
    10201885
  • 财政年份:
    2021
  • 资助金额:
    $ 111.3万
  • 项目类别:
Cincinnati Cooperative Center of Excellence in Hematology
辛辛那提血液学卓越合作中心
  • 批准号:
    10673643
  • 财政年份:
    2021
  • 资助金额:
    $ 111.3万
  • 项目类别:
Cincinnati Cooperative Center of Excellence in Hematology
辛辛那提血液学卓越合作中心
  • 批准号:
    10458590
  • 财政年份:
    2021
  • 资助金额:
    $ 111.3万
  • 项目类别:
Xenotransplant and Genome Editing Core
异种移植和基因组编辑核心
  • 批准号:
    10458592
  • 财政年份:
    2021
  • 资助金额:
    $ 111.3万
  • 项目类别:
Xenotransplant and Genome Editing Core
异种移植和基因组编辑核心
  • 批准号:
    10673647
  • 财政年份:
    2021
  • 资助金额:
    $ 111.3万
  • 项目类别:
Targeting IRAK1/4 in Myelodysplastic Syndromes
靶向治疗骨髓增生异常综合征中的 IRAK1/4
  • 批准号:
    9301788
  • 财政年份:
    2017
  • 资助金额:
    $ 111.3万
  • 项目类别:
Decoding innate immune signaling in normal and myelodysplastic hematopoiesis
解码正常和骨髓增生异常造血中的先天免疫信号
  • 批准号:
    10347307
  • 财政年份:
    2017
  • 资助金额:
    $ 111.3万
  • 项目类别:

相似海外基金

PREDICTING CARIES RISK IN UNDERSERVED CHILDREN, FROM TODDLERS TO THE SCHOOL-AGE YEARS, IN PRIMARY HEALTHCARE SETTINGS
预测初级医疗保健机构中从幼儿到学龄儿童的龋齿风险
  • 批准号:
    10361268
  • 财政年份:
    2021
  • 资助金额:
    $ 111.3万
  • 项目类别:
Predicting Caries Risk in Underserved Children, from Toddlers to the School-Age Years, in Primary Healthcare Settings
预测初级医疗机构中服务不足的儿童(从幼儿到学龄儿童)的龋齿风险
  • 批准号:
    9751077
  • 财政年份:
    2011
  • 资助金额:
    $ 111.3万
  • 项目类别:
Predicting Caries Risk in Underserved Children, from Toddlers to the School-Age Years, in Primary Healthcare Settings
预测初级医疗机构中服务不足的儿童(从幼儿到学龄儿童)的龋齿风险
  • 批准号:
    10457019
  • 财政年份:
    2011
  • 资助金额:
    $ 111.3万
  • 项目类别:
Predicting Caries Risk in Underserved Children, from Toddlers to the School-Age Years, in Primary Healthcare Settings
预测初级医疗机构中服务不足的儿童(从幼儿到学龄儿童)的龋齿风险
  • 批准号:
    9976990
  • 财政年份:
    2011
  • 资助金额:
    $ 111.3万
  • 项目类别:
Predicting Caries Risk in Underserved Children, from Toddlers to the School-Age Years, in Primary Healthcare Settings
预测初级医疗机构中服务不足的儿童(从幼儿到学龄儿童)的龋齿风险
  • 批准号:
    10213006
  • 财政年份:
    2011
  • 资助金额:
    $ 111.3万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了